GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM's CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation. T-MAXIMUM Biotech hopes to progress multiple products to the Phase II clinical research stage […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!